FFR technology poised for growth as quality, cost benefits mount

01/14/2013 | Bloomberg

Fractional flow reserve tests, which assess arterial pressure as a way to evaluate the effects of blockage, have offered physicians a more precise way to determine which patients are good candidates for stenting. That helps ensure they get optimal treatment when they need it, according to SCAI secretary Dr. James Blankenship, keeping quality high and costs relatively low. The market for FFR tests was forecast to reach $200 million in 2012 and could grow rapidly if the technology is found to have similar success in arteries in other parts of the body.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX